Spinal-supraspinal and intrinsic μ-opioid receptor agonist- norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 3, 2013, Pages 794-801

  Christoph, Thomas ^a   Schröder, Wolfgang ^a   Tallarida, Ronald J ^b   De Vry, Jean ^a   Tzschentke, Thomas M ^a  

^a GRÜNENTHAL GMBH   (Germany)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALOXONE; NORADRENALIN UPTAKE INHIBITOR; TAPENTADOL; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERALGESIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EXPERIMENTAL DIABETES MELLITUS; HYPERALGESIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SPINAL CORD; SPINAL SUPRASPINAL SYNERGY;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANALGESICS, OPIOID; ANIMALS; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HOT TEMPERATURE; HYPERALGESIA; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; MALE; MICE; MICE, INBRED C57BL; PAIN MEASUREMENT; PHENOLS; RECEPTORS, OPIOID, MU; SPINAL CORD; YOHIMBINE;

EID: 84887900595     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.207704     Document Type: Article

References (39)

1. Afilalo M and Morlion B (2013) Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician 16:27-40.
2. Bee LA, Bannister K, Rahman W., and Dickenson AH (2011) Mu-opioid and norad-renergic a(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain 152: 131-139.
3. Besse D, Lombard MC, Zajac J.M., Roques BP, and Besson JM (1990) Pre- and post-synaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res 521:15-22. (Pubitemid 20208729)
4. Bian D, Nichols ML, Ossipov M.H., Lai J., and Porreca F (1995) Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats. Neuro-report 6:1981-1984.
5. Bian D, Ossipov MH, Ibrahim M, Raffa R.B., Tallarida RJ, Malan TP, Jr, Lai J, and Porreca F (1999) Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or dynorphin an-tiserum. Brain Res 831:55-63. (Pubitemid 29336187)
6. Chen SR and Pan HL (2003) Antinociceptive effect of morphine, but not mu opioid receptor number, is attenuated in the spinal cord of diabetic rats. Anesthesiology 99:1409-1414.
7. Chen SR, Sweigart KL, Lakoski J.M., and Pan HL (2002) Functional mu opioid receptors are reduced in the spinal cord dorsal horn of diabetic rats. Anesthesiology 97:1602-1608. (Pubitemid 35417463)
8. Christoph T, De Vry J, and Tzschentke TM (2010) Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neurosci Lett 470:91-94.
9. Christoph T, Gillen C, Mika J., Grünweller A, Schäfer MK, Schiene K., Frank R, Jostock R, Bahrenberg G, and Weihe E, et al. (2007) Antinociceptive effect of an-tisense oligonucleotides against the vanilloid receptor VR1/TRPV1. Neurochem Int 50:281-290. (Pubitemid 44879686)
10. Field MJ, McCleary S, Hughes J., and Singh L (1999) Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 80:391-398. (Pubitemid 29151725)
11. Finnerup NB, Sindrup SH, and Jensen TS (2010) The evidence for pharmacological treatment of neuropathic pain. Pain 150:573-581.
12. Haley TJ and McCormick WG (1957) Pharmacological effects produced by in-tracerebral injection of drugs in the conscious mouse. Br Pharmacol Chemother 12: 12-15.
13. Hayashida K, Obata H, Nakajima K., and Eisenach JC (2008) Gabapentin acts within the locus coeruleus to alleviate neuropathic pain. Anesthesiology 109:1077-1084.
14. Hylden JL and Wilcox GL (1980) Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67:313-316. (Pubitemid 10007057)
15. Jensen TS, Backonja MM, Hernández Jiménez S, Tesfaye S, Valensi P, and Ziegler D (2006) New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 3:108-119. (Pubitemid 44638385)
16. Kawamata T, Omote K, Sonoda H., Kawamata M, and Namiki A (2000) Analgesic mechanisms of ketamine in the presence and absence of peripheral inflammation. Anesthesiology 93:520-528. (Pubitemid 30620326)
17. Kohno T, Ji RR, Ito N, Allchorne A.J., Befort K., Karchewski LA, and Woolf CJ (2005) Peripheral axonal injury results in reduced mu opioid receptor pre- and post-synaptic action in the spinal cord. Pain 117:77-87. (Pubitemid 41764774)
18. Kress HG (2010) Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 14: 781-783.
19. Kuhad A, Bishnoi M, and Chopra K (2009) Anti-nociceptive effect of duloxetine in mouse model of diabetic neuropathic pain. Indian J Exp Biol 47:193-197.
20. Lai J, Luo MC, Chen Q, Ma S., Gardell LR, Ossipov MH, and Porreca F (2006) Dynorphin A activates bradykinin receptors to maintain neuropathic pain. Nat Neurosci 9:1534-1540. (Pubitemid 44862662)
21. Loewe and Muschinek (1926) Theoretical and mathematical discussion of synergism and antagonism. Arch Exp Path Pharmacol 114:313-316.
22. Ma W and Eisenach JC (2003) Chronic constriction injury of sciatic nerve induces the up-regulation of descending inhibitory noradrenergic innervation to the lumbar dorsal horn of mice. Brain Res 970:110-118. (Pubitemid 36423186)
23. Malan TP, Ossipov MH, Gardell L.R., Ibrahim M., Bian D, Lai J, and Porreca F (2000) Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-injured rats. Pain 86:185-194. (Pubitemid 30211717)
24. Marchand F, Alloui A, Chapuy E., Hernandez A, Pelissier T, Ardid D., and Eschalier A (2003) The antihyperalgesic effect of venlafaxine in diabetic rats does not involve the opioid system. Neurosci Lett 342:105-108. (Pubitemid 36513920)
25. Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355-474. (Pubitemid 34606906)
26. Omiya Y, Suzuki Y, Yuzurihara M., Murata M, Aburada M, Kase Y., and Takeda S (2005) Antinociceptive effect of shakuyakukanzoto, a Kampo medicine, in diabetic mice. J Pharmacol Sci 99:373-380. (Pubitemid 41813429)
27. Omiya Y, Yuzurihara M, Suzuki Y., Kase Y, and Kono T (2008) Role of alpha2-adrenoceptors in enhancement of antinociceptive effect in diabetic mice. Eur J Pharmacol 592:62-66.
28. Ossipov MH, Lai J, Malan T.P., Jr, and Porreca F (2000) Spinal and supraspinal mechanisms of neuropathic pain. Ann N Y Acad Sci 909:12-24. (Pubitemid 30462030)
29. Rashid MH, Inoue M, Toda K., and Ueda H (2004) Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain. J Pharmacol Exp Ther 309:380-387. (Pubitemid 38393151)
30. Roerig SC and Fujimoto JM (1989) Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice. J Pharmacol Exp Ther 249:762-768. (Pubitemid 19166655)
31. Scherrer G, Imamachi N, Cao Y.Q., Contet C., Mennicken F, O'Donnell D, Kieffer BL, and Basbaum AI (2009) Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 137:1148-1159.
32. Schröder W., Tzschentke TM, Terlinden R, De Vry J, Jahnel U, Christoph T., and Tallarida RJ (2011) Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 337:312-320.
33. Schröder W., Vry JD, Tzschentke T.M., Jahnel U., and Christoph T (2010) Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 14:814-821.
34. Tallarida RJ, Porreca F, and Cowan A (1989) Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci 45:947-961. (Pubitemid 19251921)
35. Tzschentke TM, Christoph T, Kögel B, Schiene K., Hennies HH, Englberger W, Haurand M, Jahnel U., Cremers TI, and Friderichs E, et al (2007) (-)-(1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 323:265-276. (Pubitemid 47443277)
36. Tzschentke TM, De Vry J, Terlinden R, Hennies H.H., Lange C., Strassburger W, Haurand M, Kolb J., Schneider J, and Buschmann H, et al. (2006) Tapentadol hydrochloride. Drugs Future 31:1053-1061.
37. Wigdor S and Wilcox GL (1987) Central and systemic morphine-induced anti-nociception in mice: contribution of descending serotonergic and noradrenergic pathways. J Pharmacol Exp Ther 242:90-95. (Pubitemid 17112264)
38. Yeung JC and Rudy TA (1980) Multiplicative interaction between narcotic agonisms expressed at spinal and supraspinal sites of antinociceptive action as revealed by concurrent intrathecal and intracerebroventricular injections of morphine. J Pharmacol Exp Ther 215:633-642. (Pubitemid 11210370)
39. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109-110. (Pubitemid 13058546)